Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева yubykov@gmail.com
Список исп. литературыСкрыть список 1. Беккер Р.А., Быков Ю.В. Акатизия: клинический анализ патологии с рекомендациями и обзором литературы. Consilium Medicum. http://con-med.ru/upload/iblock/eaa/psi_akatisia2. pdf / Bekker R.A., Bykov Iu.V. Akatiziia: klinicheskii analiz patologii s rekomendatsiiami i obzorom literatury. Consilium Medicum. http://con-med. ru/upload/iblock/eaa/psi_akatisia2. pdf [in Russian] 2. Беккер Р.А., Ханнанова А.Н., Быков Ю.В. Может ли мелатонин эффективно использоваться для коррекции побочных эффектов различных психотропных лекарств и электросудорожной терапии? В мире научных открытий. 2017; 9 (4): 174–204. / Bekker R.A., Khannanova A.N., Bykov Iu.V. Mozhet li melatonin effektivno ispol'zovat'sia dlia korrektsii pobochnykh effektov razlichnykh psikhotropnykh lekarstv i elektrosudorozhnoi terapii? V mire nauchnykh otkrytiy. 2017; 9 (4): 174–204. [in Russian] 3. Левин Я.И. Мелатонин и неврология. РМЖ. 2007; 15 (24): 1851–5. / Levin Ia.I. Melatonin i nevrologiia. RMZh. 2007; 15 (24): 1851–5. [in Russian] 4. Левин Я.И. Мелатонин и сосудистые заболевания головного мозга. РМЖ. Неврология и психиатрия. 2008; 26: 1732–4. / Levin Ia.I. Melatonin i sosudistye zabolevaniia golovnogo mozga. RMZh. Nevrologiia i psikhiatriia. 2008; 26: 1732–4. [in Russian] 5. Левин Я.И. Опыт применения агомелатина (вальдоксана) в неврологической практике. Журн. неврологии и психиатрии им. C.C.Корсакова. 2011; 111 (11): 25–8. / Levin Ia.I. Opyt primeneniia agomelatina (val'doksana) v nevrologicheskoi praktike. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2011; 111 (11): 25–8. [in Russian] 6. Abbas S, Chandra PS, Srivastava M. The use of fluoxetine and buspirone for treatment-refractory depersonalization disorder. J Clin Psychiatry 1995; 56 (10): 484. 7. Afonso P, Brissos S, Figueira ML, Paiva T. Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep. Schizophr Res 2010; 120: 227–8. 8. Altınyazar V, Kiylioglu N. Insomnia and dementia: is agomelatine treatment helpful? Case report and review of the literature. Ther Adv Psychopharmacol 2016; 6 (4): 263–8. 9. Antoniadis D, Floros GD, Nikolaidis N, Garyfallos G. Response to agomelatine: treatment of an obsessive skin picking episode. Ann Clin Psychiatry 2013; 25 (3): 228–9. 10. Avila A, Cardona X, Martin-Baranera M et al. Agomelatine for Depression in Parkinson Disease: Additional Effect on Sleep and Motor Dysfunction. J Clin Psychopharmacol 2015; 35 (6): 719–23. 11. Aydın TH, Can ÖD, Demir Özkay Ü, Turan N. Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms.Fundam Clin Pharmacol 2016; 30 (6): 549–67. 12. Bhutada P, Dixit P, Thakur K et al. Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam. Kaohsiung J Med Sci 2013; 29 (7): 362–7. 13. Bout A, Berhili N, Benbrahim M et al. Lamotrigine in the treatment of resistant depersonalization disorder: A case report. Article in French. Encephale 2017; pii: S0013-7006 (17)30113-6 14. Bruno A, Micò U, Lorusso S et al. Agomelatine in the treatment of fibromyalgia: A 12-week, open-label, uncontrolled preliminary study. J Clin Psychopharmacol 2013; 33: 507–11. 15. Bruno A, Zoccali RA, Abenavoli E et al. Augmentation of clozapine with agomelatine in partial-responder schizophrenia: A 16-week, open-label, uncontrolled pilot study. J Clin Psychopharmacol 2014; 34: 491–4. 16. Calandre EP, Slim M, Garcia-Leiva JM et al. Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: An uncontrolled, 12-week, pilot study. Pharmacopsychiatry 2014; 47: 67–72. 17. Callegari I, Mattei C, Benassi F et al. Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegener Dis 2016; 16 (5–6): 352–6. 18. Chernova EV, Kozhechkina OV, Ter-Israelyan AY, Medvedev VE. Agomelatine (valdoxan) in treatment of endogenous depression in day patient department. Article in Russian. Zh Nevrol Psikhiatr Im S.S.Korsakova. 2016; 116 (10): 43–6. 19. Chumboatong W, Thummayot S, Govitrapong P et al. Neuroprotection of agomelatine against cerebral ischemia/reperfusion injury through an antiapoptotic pathway in rat. Neurochem Int 2017; 102: 114–22. 20. Crippa JA, Hallak JE, Zuardi AW et al. Agomelatine in the treatment of social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1357–8. 21. Da Rocha FF, Correa H. Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD. Clin Neuropharmacol 2011; 34: 139–40. 22. De Berardis D, Acciavatti T, di Iorio G et al. The melatonergic system: Effects on sleep and implications for the treatment of psychiatric disorders. ChronoPhysiol Ther 2011; 1: 59–67. 23. De Berardis D, Conti CM, Marini S et al. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data. Int J Immunopathol Pharmacol. 2013; 26 (2): 299–304. 24. De Berardis D, Fornaro M, Serroni N et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci 2015; 16 (1): 1111–30. 25. De Berardis D, Marini S, Fornaro M et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: Implications for clinical practice. Int J Mol Sci 2013; 14: 12458–83. 26. De Berardis D, Serroni N, Campanella D et al. A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. J Clin Psychopharmacol 2012; 32: 289–90. 27. De Berardis D, Serroni N, Marini S et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry 2012; 2012: 642752. 28. De Berardis D, Serroni N, Marini S et al. Agomelatine for the treatment of posttraumatic stress disorder: A case report. Ann Clin Psychiatry 2012; 24: 241–2. 29. De Berardis D, Valchera A, Fornaro M et al. Agomelatine reversal of escitalopram-induced apathy: A case report. Psychiatry Clin Neurosci 2013; 67: 190–1. 30. Di Giannantonio M, Martinotti G. Anhedonia and major depression: The role of agomelatine. Eur Neuropsychopharmacol 2012; 22: 505–10. 31. Egorov AY. The use of agomelatine (valdoxan) in gambling therapy: a pilot study. [Article in Russian]. Zh Nevrol Psikhiatr Im S.S.Korsakova. 2015; 115 (9): 28–31. 32. Englisch S, Jung HS, Lewien A et al. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study. J Clin Psychopharmacol 2016; 36 (6): 597–607. 33. Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf 2014. 34. Foguet Q, Alvárez MJ, Castells E, Arrufat F. Methylphenidate in depersonalization disorder: a case report. Actas Esp Psiquiatr 2011; 39 (1): 75–8. 35. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8: 287–304. 36. Fornaro M. Agomelatine in the treatment of panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 (1): 286–7. 37. Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann Gen Psychiatry 2011; 10 (1): 5. 38. Grosshans M, Mutschler J, Kiefer F. Treatment of severe sleep disorder related to alcohol-dependence with high-dose agomelatine. A case report. Psychiatr Danub 2013; 25: 416–8. 39. Grosshans M, Mutschler J, Luderer M et al. Agomelatine is effective in reducing insomnia in abstinent alcohol-dependent patients. Clin Neuropharmacol 2014; 37: 6–8. 40. Gruca P, Przegalinski E, Mrowiec S et al. Evidence for antidepressant and anxiolytic-like activities of melatonin and agomelatine in animal models. Eur Neuropsychopharmacol 2004; 14: S230. 41. Guglielmo R, Martinotti G, di Giannantonio M, Janiri L. A possible new option for migraine management: Agomelatine. Clin Neuropharmacol 2013; 36: 65–7. 42. Gupta S, Sharma B. Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease. Pharmacol Biochem Behav 2014; 122: 122–35. 43. Gupta S, Singh P, Sharma BM, Sharma B. Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia. Curr Neurovasc Res 2015; 12 (3): 240–52. 44. Heun R, Ahokas A, Boyer P et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 2013; 74 (6): 587–94. 45. Huijbregts KM, Batelaan NM, Schonenberg J et al. Agomelatine as a novel treatment option in panic disorder, results from an 8-week open-label trial. J Clin Psychopharmacol 2015; 35 (3): 336–8. 46. Hussain SA, Al-Khalifa II, Jasim NA, Gorial FI. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011; 50: 267–71. 47. Karakaş A, Coşkun H, Kaya A et al. The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats. Behav. Brain Res 2011; 222: 141–50. 48. Koresh O, Kozlovsky N, Kaplan Z et al. The long-term abnormalities in circadian expression of Period 1 and Period 2 genes in response to stress is normalized by agomelatine administered immediately after exposure. Eur Neuropsychopharmacol 2012; 22 (3): 205–21. 49. Lange KW, Lange KM, Hauser J et al. Circadian rhythms in obsessive-compulsive disorder. J Neural Transm (Vienna) 2012; 119 (10): 1077–83. 50. Levitan MN, Papelbaum M, Nardi AE. A review of preliminary observations on agomelatine in the treatment of anxiety disorders. Exp Clin Psychopharmacol 2012; 20 (6): 504–9. 51. Levitan MN, Papelbaum M, Nardi AE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2015; 11: 1149–55. 52. Levitan MN, Papelbaum M, Soares G et al. Agomelatine in Panic Disorder: A 6-Week Follow-Up Case Series. J Clin Psychopharmacol 2016; 36 (4): 395–6. 53. Li X, Borjigin J, Snyder SH. Molecular rhythms in the pineal gland. Curr Opin Neurobiol 1998; 8: 648–51. 54. Liu J, Clough SJ, Hutchinson AJ et al. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol 2016; 56: 361–83. 55. Martinotti G, di Iorio G, Marini S et al. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: A review. J Biol Regul Homeost Agents 2012; 26: 347–56. 56. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5-HT2C receptor blockade. Psychopharmacology 2005; 177: 448–58. 57. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64. 58. Monti JM, BaHammam AS, Pandi-Perumal SR et al. Sleep and circadian rhythm dysregulation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 43: 209–16. 59. Morera-Fumero AL, Abreu-Gonzalez P. Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression. J Clin Psychopharmacol 2010; 30: 739–41. 60. Morera-Fumero AL, Abreu-Gonzalez P. Role of melatonin in schizophrenia. Int J Mol Sci 2013; 14: 9037–50. 61. Müller H, Seifert F, Maler JM et al. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients. Singapore Med J 2012; 53 (11): e228–30. 62. Mutschler J, Rüsch N, Schönfelder H et al. Agomelatine for Depression in Schizophrenia: A Case-Series. Psychopharmacol Bull 2012; 45 (1): 35–43. 63. Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: A double-blinded, placebo-controlled study. Anesth Analg 2000; 91: 473–9. 64. Niederhofer H. Agomelatine treatment with adolescents with ADHD. J Atten Disord 2012; 16 (6): 530–2. 65. Palacios JM, Pazos A, Hoyer D. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology (Berl) 2017; 234 (9–10): 1395–418. 66. Pandi-Perumal SR, Srinivasan V et al. Melatonin: nature’s most versatile biological signal? FEBS J 2006; 273: 2813–38. 67. Pardini M, Cordano C, Benassi F et al. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. Eur Neuropsychopharmacol 2014; 24 (6): 939–44. 68. Park HJ, Park JK, Kim SK et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 2011; 45: 304–8. 69. Peres MF, Zukerman E, da Cunha Tanuri F et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004; 63: 757. 70. Perna G, Alciati A, Riva A et al. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep 2016; 18 (3): 23. 71. Pernambuco AP, Schetino LP, Viana RS et al. The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol 2014 in press. 72. Perugi G, Quaranta G, Bucci N. The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms. Expert Opin Investig Drugs 2015; 24 (5): 705–13. 73. Pizarro M, Fontenelle LF, Paravidino DC et al. An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder. Expert Opin Pharmacother 2014; 15 (10): 1391–401. 74. Sachdev P. Citalopram-Clonazepam combination for primary depersonalization disorder: a case report. Aust N Z J Psychiatry 2002; 36 (3): 424–5. 75. Salardini E, Zeinoddini A, Kohi A et al. Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial. J Child Adolesc Psychopharmacol 2016; 26 (6): 513–9. 76. San L, Arranz B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008; 23: 396–402. 77. Scarella TM, Franzen JR. Case report: Improvement in dissociative symptoms with mixed amphetamine salts. J Trauma Dissociation 2017; 18 (5): 649–62. 78. Sierra M. Depersonalization disorder: pharmacological approaches. Expert Rev Neurother 2008; 8 (1): 19–26. 79. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. Cambridge University Press. 1st Ed 2012. 80. Signorelli MS, Concerto C, Battaglia E et al. Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors. SAGE Open Med Case Rep 2014; 2: 2050313X14561778. 81. Srinivasan V, Lauterbach EC, Ho KY et al. Melatonin in antinociception: Its therapeutic applications. Curr Neuropharmacol 2012; 10: 167–78. 82. Stein DJ, Ahokas A, Albarran C et al. Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012; 73: 1002–8. 83. Stein DJ, Ahokas A, Jarema M et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2017; 27 (5): 526–37. 84. Stein DJ, Ahokas A, Márquez MS et al. Agomelatine in generalized anxiety disorder: An active comparator and placebo-controlled study. J Clin Psychiatry 2014; 75: 362–8. 85. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561–6. 86. Tabeeva GR, Sergeev AV, Gromova SA. Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2C receptor antagonist agomelatin (valdoxan) Zh. Nevrol. Psikhiatr. Im. S.S.Korsakova. 2011; 111: 32–6. 87. Tchekalarova J, Atanasova D, Nenchovska Z et al. Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy. Neurobiol Dis 2017; 104: 1–14. 88. Thome J, Foley P. Agomelatine: an agent against anhedonia and abulia? J Neural Transm (Vienna) 2015; 122 (Suppl. 1): S3–7. 89. Tzavellas E, Karaiskos D, Ilias I et al. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report. Psychiatriki 2014; 25 (3): 179–84. 90. Vimala PV, Bhutada PS, Patel FR. Therapeutic potential of agomelatine in epilepsy and epileptic complications. Med Hypotheses 2014; 82 (1): 105–10. 91. Waldinger MD. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol 2015; 130: 469–89. 92. Wilhelmsen M, Amirian I, Reiter RJ et al. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. J Pineal Res 2011; 51: 270–7. 93. Zapp AA, Fischer EC, Deuschle M. The effect of agomelatine and melatonin on sleep-related eating: a case report. J Med Case Rep 2017; 11 (1): 275.